175 related articles for article (PubMed ID: 32388064)
1. Adjuvant immunotherapy: the sting in the tail.
Higham CE; Chatzimavridou-Grigoriadou V; Fitzgerald CT; Trainer PJ; Eggermont AMM; Lorigan P
Eur J Cancer; 2020 Jun; 132():207-210. PubMed ID: 32388064
[TBL] [Abstract][Full Text] [Related]
2. Feasibility of high-dose interferon-alpha2b adjuvant therapy for high-risk resected cutaneous melanoma.
Muggiano A; Mulas C; Fiori B; Liciardi G; Pintus M; Tanca L; Tedde A; Turno R; Desogus A
Melanoma Res; 2004 Apr; 14(2):S1-7. PubMed ID: 15057049
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
4. Updates in adjuvant systemic therapy for melanoma.
Kwak M; Farrow NE; Salama AKS; Mosca PJ; Hanks BA; Slingluff CL; Beasley GM
J Surg Oncol; 2019 Jan; 119(2):222-231. PubMed ID: 30481375
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria RN; Prieto PA; Tetzlaff MT; Reuben A; Andrews MC; Ross MI; Glitza IC; Cormier J; Hwu WJ; Tawbi HA; Patel SP; Lee JE; Gershenwald JE; Spencer CN; Gopalakrishnan V; Bassett R; Simpson L; Mouton R; Hudgens CW; Zhao L; Zhu H; Cooper ZA; Wani K; Lazar A; Hwu P; Diab A; Wong MK; McQuade JL; Royal R; Lucci A; Burton EM; Reddy S; Sharma P; Allison J; Futreal PA; Woodman SE; Davies MA; Wargo JA
Lancet Oncol; 2018 Feb; 19(2):181-193. PubMed ID: 29361468
[TBL] [Abstract][Full Text] [Related]
7. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
9. Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy.
O'Regan KN; Jagannathan JP; Ramaiya N; Hodi FS
AJR Am J Roentgenol; 2011 Aug; 197(2):W241-6. PubMed ID: 21785048
[TBL] [Abstract][Full Text] [Related]
10. Pros and cons of adjuvant interferon in the treatment of melanoma.
Sabel MS; Sondak VK
Oncologist; 2003; 8(5):451-8. PubMed ID: 14530498
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Maio M; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan P; Ibrahim N; Marreaud S; van Akkooi ACJ; Suciu S; Robert C
N Engl J Med; 2018 May; 378(19):1789-1801. PubMed ID: 29658430
[TBL] [Abstract][Full Text] [Related]
13. Considering adjuvant therapy for stage II melanoma.
Poklepovic AS; Luke JJ
Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
15. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
16. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant systemic therapy in high-risk melanoma.
Blankenstein SA; van Akkooi ACJ
Melanoma Res; 2019 Aug; 29(4):358-364. PubMed ID: 30896556
[TBL] [Abstract][Full Text] [Related]
18. [Phase II clinical trial of autologous dendritic cell vaccine with immunologic adjuvant in cutaneous melanoma patients].
Baldueva IA; Novik AV; Moiseenko VM; Nekhaeva TL; Danilova AB; Danilov AO; Protsenko SA; Petrova TIu; Uleĭskaia GI; Shchekina LA; Semenova AI; Mikhaĭlichenko TD; Teletaeva GM; Zhabina AS; Volkov NV; Komarov IuI
Vopr Onkol; 2012; 58(2):212-21. PubMed ID: 22774527
[TBL] [Abstract][Full Text] [Related]
19. Systemic Therapy Options for Patients With Unresectable Melanoma.
Yushak M; Chapman P; Robert C; Kudchadkar R
Am Soc Clin Oncol Educ Book; 2017; 37():661-672. PubMed ID: 28561662
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapies in the treatment of stage II and III malignant melanoma.
Kavanagh D; Hill AD; Djikstra B; Kennelly R; McDermott EM; O'Higgins NJ
Surgeon; 2005 Aug; 3(4):245-56. PubMed ID: 16121769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
